资讯

Sarepta Therapeutics Acknowledges CHMP Negative Opinion for ELEVIDYS in the European Union
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, acknowledges that the ...
The Manila Times23 分钟
Intelligent Bio Solutions Inc. Enters Into Agreements to Raise $3.8 Million in Gross Proceeds
Proceeds to Fund Completion of the Company’s 510k Filing with the U.S. FDA for its Fingerprint Drug Screening System ...
PharmiWeb32 分钟
Understanding The Growth Of The Companion Diagnostics Industry By 2035
Overview of Companion Diagnostics MarketThe Companion Diagnostics Market is evolving rapidly, driven by the growing demand ...
Pharmabiz32 分钟
Health Canada approves Clearside Biomedical’s Xipere for suprachoroidal treatment for ...
Health Canada approves Clearside Biomedical’s Xipere for suprachoroidal treatment for uveitic macular edema: Alpharetta, Georgia Friday, July 25, 2025, 18:00 Hrs [IST] Clearside ...
EU regulator approves injectable HIV drug that experts say could help stop transmission
The European Medicines Agency has recommended authorizing a twice-yearly injectable drug to prevent HIV. Scientists say this ...
PharmTech1 小时
CMC and Analytical Gaps in CRLs: Why They Persist Despite FDA Guidance and How You Can ...
Many companies face FDA complete response letters due to ongoing chemistry, manufacturing, and controls, or CMC, and ...
BioSpace1 小时
Sarepta’s Future Increasingly Uncertain as FDA Eyes New Study for Elevidys
CBER is unanimously against Elevdiys’ return to the market without additional evidence, according to media reports citing an ...